263 related articles for article (PubMed ID: 35371002)
1. CD56-Negative Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Study in 443 Patients Treated by Chemotherapy With or Without Asparaginase.
Yang J; Li P; Piao Y; Liu X; Wei L; Sang W; Zhang L; Wang L
Front Immunol; 2022; 13():829366. PubMed ID: 35371002
[TBL] [Abstract][Full Text] [Related]
2. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.
Wang L; Wang H; Wang JH; Xia ZJ; Lu Y; Huang HQ; Jiang WQ; Zhang YJ
Oncotarget; 2015 Oct; 6(30):30317-26. PubMed ID: 26210287
[TBL] [Abstract][Full Text] [Related]
3. [Clinical differences between primary nasopharyngeal NK/T-cell lymphoma and primary nasal cavity NK/T-cell lymphoma with nasopharynx extension].
Liu WX; Liu YP; Jin J; Wang SL; Fang H; Ren H; Song YW; Chen B; Lu NN; Li N; Tang Y; Qi SN; Tang Y; Wang WH; Li YX
Zhonghua Zhong Liu Za Zhi; 2019 Jan; 41(1):56-62. PubMed ID: 30678418
[No Abstract] [Full Text] [Related]
4. Circulating Low Absolute CD4+ T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy.
Zhang YP; Zhang R; Zhu HY; Wang L; Wu YJ; Liang JH; Shi WY; Liu H; Xu W; Li JY
Cancer Res Treat; 2019 Jan; 51(1):368-377. PubMed ID: 29764116
[TBL] [Abstract][Full Text] [Related]
5. SLC1A1 mediated glutamine addiction and contributed to natural killer T-cell lymphoma progression with immunotherapeutic potential.
Xiong J; Wang N; Zhong HJ; Cui BW; Cheng S; Sun R; Chen JY; Xu PP; Cai G; Wang L; Sun XJ; Huang JY; Zhao WL
EBioMedicine; 2021 Oct; 72():103614. PubMed ID: 34628354
[TBL] [Abstract][Full Text] [Related]
6. PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity.
Zheng W; Gao Y; Ke X; Zhang W; Su L; Ren H; Lin N; Xie Y; Tu M; Liu W; Ping L; Ying Z; Zhang C; Deng L; Wang X; Song Y; Zhu J
BMC Cancer; 2018 Sep; 18(1):910. PubMed ID: 30241515
[TBL] [Abstract][Full Text] [Related]
7. [Long-term effect of risk-adaptive therapy for early stage extranodal NK/T cell lymphoma].
Wu T; Liu QL; Hu YF; Zhang J; Chen MX; Chen XX; Huang YH; Lu B
Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):859-864. PubMed ID: 31770855
[No Abstract] [Full Text] [Related]
8. Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical Trial.
Wang X; Zhang L; Liu X; Li X; Li L; Fu X; Sun Z; Wu J; Zhang X; Yan J; Chang Y; Nan F; Zhou Z; Wu X; Tian L; Ma M; Li Z; Yu H; Zhu L; Wang Y; Shi C; Feng X; Li J; Ding M; Zhang J; Dong M; Xue H; Wang J; Zou L; Su L; Wu J; Liu L; Bao H; Zhang L; Guo Y; Guo S; Lu Y; Young KH; Li W; Zhang M
JAMA Oncol; 2022 Jul; 8(7):1035-1041. PubMed ID: 35708709
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcome of patients with advanced stage natural killer/T-cell lymphoma: elucidating the effects of asparaginase and postchemotherapeutic radiotherapy.
Bi XW; Jiang WQ; Zhang WW; Huang JJ; Xia Y; Wang Y; Sun P; Li ZM
Ann Hematol; 2015 Jul; 94(7):1175-84. PubMed ID: 25687842
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes of patients treated with an EPOCHL regimen as first-line chemotherapy for newly diagnosed extranodal natural killer/T-cell lymphoma: a retrospective single-center study.
Wei L; Wang J; Ye J; Yang L; Cong J; Li X; Wu Y; Cui X; Ding J; Yao N; Yang J
Leuk Lymphoma; 2020 Feb; 61(2):337-343. PubMed ID: 31517553
[TBL] [Abstract][Full Text] [Related]
11. Immunophenotypic and clinical differences between the nasal and extranasal subtypes of upper aerodigestive tract natural killer/T-cell lymphoma.
Liu QF; Wang WH; Wang SL; Liu YP; Huang WT; Lu N; Zhou LQ; Ouyang H; Jin J; Li YX
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):806-13. PubMed ID: 24495590
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and survival of extranodal natural killer/T-cell lymphoma: a single-center 12-year retrospective analysis.
Chen Y; Luo L; Zheng X; Fu H; Yang X; Huang W; Chen L; Zheng Z; Zheng J; Yang T; Liu T; Hu J
Leuk Lymphoma; 2020 Dec; 61(14):3306-3318. PubMed ID: 32820684
[TBL] [Abstract][Full Text] [Related]
13. Early radiotherapy has an essential role for improving survival in patients with stage I-II nasal-type of NK/T cell lymphoma treated with L-asparaginase-containing chemotherapy--a single institution experience.
Zang J; Li C; Luo SQ; Wang JH; Xu M; Zhao LN; Li WW; Yang H; Xiao F; Hitchcock YJ; Shi M
Ann Hematol; 2015 Apr; 94(4):583-91. PubMed ID: 25409913
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerance of GELOXD/P-GEMOXD in newly diagnosed nasal-type extranodal NK/T-cell lymphoma: A multicenter retrospective study.
Li JW; Li YJ; Zhong MZ; Liu XL; Li J; Li KL; Liu XY; Zhou F; OuYang Z; Sun ZY; Huang LJ; He JQ; Zhou H; Yi PY
Eur J Haematol; 2018 Mar; 100(3):247-256. PubMed ID: 29194798
[TBL] [Abstract][Full Text] [Related]
15. CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis.
Wang L; Wang Z; Xia ZJ; Lu Y; Huang HQ; Zhang YJ
Tumour Biol; 2015 Sep; 36(10):7717-23. PubMed ID: 25935537
[TBL] [Abstract][Full Text] [Related]
16. Clinical disparity and favorable prognoses for patients with Waldeyer ring extranodal nasal-type NK/T-cell lymphoma and diffuse large B-cell lymphoma.
Wu RY; Li YX; Wang WH; Jin J; Wang SL; Liu YP; Song YW; Fang H; Ren H; Liu QF; Wang ZY; Qi SN; Lu NN; Chen B; Zhang XM; Zhou LQ; Liu XF; Yu ZH
Am J Clin Oncol; 2014 Feb; 37(1):41-6. PubMed ID: 22992625
[TBL] [Abstract][Full Text] [Related]
17. L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type.
Yong W; Zheng W; Zhu J; Zhang Y; Wang X; Xie Y; Lin N; Xu B; Lu A; Li J
Ann Hematol; 2009 Jul; 88(7):647-52. PubMed ID: 19107482
[TBL] [Abstract][Full Text] [Related]
18. Genomic features reveal potential benefit of adding anti-PD-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphoma.
Chen Z; Huang H; Huang H; Yu L; Weng H; Xiao J; Zou L; Zhang H; Liang C; Zhou H; Guo H; Wang Z; Li Z; Wu T; Zhang H; Wu H; Peng Z; Zhai L; Chen X; Liang Y; Hong H; Lin T
Leukemia; 2024 Apr; 38(4):829-839. PubMed ID: 38378844
[TBL] [Abstract][Full Text] [Related]
19. Utility of baseline, interim and end-of-treatment
Chang Y; Fu X; Sun Z; Xie X; Wang R; Li Z; Zhang X; Sheng G; Zhang M
Sci Rep; 2017 Jan; 7():41057. PubMed ID: 28117395
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors and treatment outcomes for patients with stage II extranodal nasal-type natural killer/T-cell lymphoma of the upper aerodigestive tract.
Fang H; Jin J; Wang WH; Wang SL; Zhou LQ; Li YX
Leuk Lymphoma; 2014 Aug; 55(8):1832-7. PubMed ID: 24144309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]